| Assessment Status | Rapid Review complete |
| HTA ID | 24011 |
| Drug | Enalapril maleate |
| Brand | Aqumeldi® |
| Indication | For the treatment of heart failure in children and adolescents from birth to less than 18 years of age. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2024 |
| Rapid review completed | 12/04/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that enalapril maleate mini ODTs not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
